Department of Virology, Institute of Experimental Medicine, 12 Acad. Pavlov Street, Saint Petersburg 195220, Russia.
Vaccine. 2013 Oct 1;31(42):4702-5. doi: 10.1016/j.vaccine.2013.08.040. Epub 2013 Aug 26.
After recent emergence of new avian influenza A(H7N9) viruses in humans many people and Governments are asking about H7 influenza vaccine which could provide cross-protection against new viruses, until H7N9 vaccine is prepared from a relevant strain. Here we scientifically justify that available H7N3 live attenuated influenza vaccine (LAIV) can be protective against H7N9 viruses due to the presence of conserved immune epitopes in its hemagglutinin. We used Immune Epitope Database analysis resource to predict B-cell and CTL epitopes distributed across H7N3 HA molecule and assessed their identity with new H7N9 viruses at near 70% and 60% of the epitopes, respectively. In addition, we tested serum samples of volunteers participated in phase I clinical trial of H7N3 LAIV for the presence of anti-H7N9 hemagglutination-inhibition and neutralizing antibodies and found seroconversions in 44.8% of vaccinated persons, which suggests the potential of H7N3 LAIV to protect against new H7N9 avian influenza viruses.
最近在人类中出现了新型甲型禽流感病毒（H7N9）之后，许多人和政府都在询问 H7 流感疫苗，这种疫苗可以提供针对新病毒的交叉保护，直到制备出针对 H7N9 的相关疫苗。在这里，我们从科学上证明，现有的 H7N3 减毒活流感疫苗（LAIV）可以对 H7N9 病毒提供保护，因为其血凝素中存在保守的免疫表位。我们使用免疫表位数据库分析资源来预测分布在 H7N3 HA 分子上的 B 细胞和 CTL 表位，并分别评估它们与新的 H7N9 病毒的同源性，分别为近 70%和 60%的表位。此外，我们测试了参加 H7N3 LAIV 一期临床试验的志愿者的血清样本，以检测针对 H7N9 的血凝抑制和中和抗体，发现接种者中有 44.8%发生血清转换，这表明 H7N3 LAIV 有潜力预防新的 H7N9 禽流感病毒。
